Mithra Signs LSA for Commercialization of Myring™ in Germany, the biggest market in Europe

  • Mithra grants exclusive license to Hormosan for commercialization of vaginal contraceptive ring in Germany
  • Germany is the largest European market in terms of volumes, with 3 million vaginal rings sold per year
  • Agreement follows licensing deals for Myring™ with market leaders in the U.S., Europe, Russia, Australia, Middle East, Latin and South America

Liege, Belgium, 28 May 2019 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into an exclusive license and supply agreement with Hormosan for the commercialization of its hormonal contraceptive ring Myring™, bioequivalent to Nuvaring®, in Germany. Hormosan is a subsidiary of the innovation-driven pharmaceutical company Lupin Group, offering low-cost generics in Germany that offer added value relevant to therapy.